Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
Conditions
Graves' Disease
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Site 112, Gilbert, Arizona, United States
Site 130, Phoenix, Arizona, United States
Site 121, La Mesa, California, United States
Site 125, Orange, California, United States
Site 103, Sacramento, California, United States
Site 111, San Francisco, California, United States
Site 105, Torrance, California, United States
Site 109, Miami Lakes, Florida, United States
Site 115, Palm Harbor, Florida, United States
Site 123, Sarasota, Florida, United States
Site 118, Macon, Georgia, United States
Site 122, Bowling Green, Kentucky, United States
Site 126, Flint, Michigan, United States
Site 107, Livonia, Michigan, United States
Site 108, Omaha, Nebraska, United States
Site 129, Niagara Falls, New York, United States
Site 120, Orchard Park, New York, United States
Site 104, Columbus, Ohio, United States
Site 124, Sayre, Pennsylvania, United States
Site 100, Amarillo, Texas, United States
Site 117, Conroe, Texas, United States
Site 128, Edinburg, Texas, United States
Site 127, El Paso, Texas, United States
Site 106, Fort Worth, Texas, United States
Site 110, Houston, Texas, United States
Site 101, Humble, Texas, United States
Site 116, San Antonio, Texas, United States
Site 119, Chesapeake, Virginia, United States
Site 151, East Melbourne, Victoria, Australia
Site 150, Melbourne N., Victoria, Australia